Psychedelic Drug Discovery Gets a New Preclinical Framework

Psychedelic drug discovery is entering a new, more mature phase. While clinical trials of psilocybin and lysergic acid diethylamide (LSD) continue to generate encouraging results for depression, anxiety, and substance use disorders, researchers are increasingly focused on improving how the next generation of psychedelic-inspired medicines is discovered.

Image

Why Psychedelic Drug Discovery Needs a New Framework

Interest in psychedelic therapeutics has grown rapidly over the past decade, driven by promising clinical evidence and a renewed understanding of how these compounds affect the brain.

Yet developing medicines for psychiatric disorders remains one of the most difficult areas of pharmaceutical research.

Unlike many therapeutic areas, central nervous system (CNS) drug discovery faces exceptionally high attrition rates, partly because preclinical models often fail to predict clinical outcomes.

Psychedelic medicines introduce additional complexity because they produce intertwined pharmacological, behavioural, and neurobiological effects that cannot be captured using a single experimental model.

A recent review published in Trends in Pharmacological Sciences argues that the future of psychedelic drug discovery progress will depend less on finding new psychedelic compounds and more on developing robust, translational preclinical assays that better predict therapeutic success in humans.

The review argues that relying on one assay, one receptor, or one behavioural endpoint risks overlooking critical aspects of a compound's therapeutic profile.

Instead, researchers propose an integrated framework built around three complementary domains:

• Receptor pharmacology (agonism)
• Behavioural pharmacology
• Cellular and neural plasticity

Together, these domains provide a more comprehensive understanding of how psychedelic-inspired compounds may perform before they enter expensive clinical development.

Image

The First Pillar: Understanding CNS Receptor Pharmacology

Every drug discovery programme begins by understanding how a molecule interacts with its biological target.

For classic psychedelics such as psilocybin and LSD, the primary target is the 5-HT2A serotonin receptor.

Activation of this receptor has long been associated with the characteristic psychological effects of psychedelic compounds and is believed to play an important role in their therapeutic activity.

However, the review emphasises that receptor binding alone tells only part of the story.

Modern pharmacology has revealed that different compounds can activate the same receptor in different ways, producing distinct downstream signalling pathways.

This phenomenon, known as biased agonism, may help explain why some compounds produce strong hallucinogenic effects while others could potentially deliver therapeutic benefits with reduced psychoactivity.

Recent advances highlighted in the review include:

• high-throughput receptor screening
• engineered biosensors
• structure-based drug design
• computational ligand discovery
• improved pharmacological profiling

These technologies allow researchers to screen far larger libraries of candidate molecules while characterising receptor activity with much greater precision than traditional assays.

For pharmaceutical companies, this means that candidate selection can increasingly focus on functional signalling profiles, rather than simply receptor affinity.

The Second Pillar: Measuring Behaviour and Pharmacology that Matters

A promising receptor profile does not automatically translate into therapeutic benefit.

The second component of the proposed framework focuses on behavioural pharmacology, using carefully designed animal models to evaluate how psychedelic compounds influence behaviour relevant to psychiatric disorders.

Historically, one of the most widely used assays has been the head-twitch response (HTR) in rodents.

Activation of the 5-HT2A receptor produces a rapid head movement that has become a commonly used indicator of psychedelic activity.

Although the assay is valuable for confirming receptor engagement, the authors stress that it should not be treated as a direct measure of therapeutic efficacy.

Instead, behavioural testing is expanding to include a wider range of endpoints.

These include assessments of:

• cognitive flexibility
• fear extinction
• stress resilience
• social behaviour
• learning and memory
• reward processing

Using multiple behavioural paradigms enables researchers to distinguish compounds that merely activate psychedelic pathways from those that may produce clinically meaningful improvements.

Importantly, the review also notes that newer behavioural technologies, including automated tracking systems and machine learning-based behavioural analysis, are improving both reproducibility and throughput in preclinical research.

View interview AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.

Image

The Third Pillar: Neural Plasticity as a Therapeutic Target

Perhaps the most significant development in psychedelic drug discovery has been growing evidence that many psychedelic compounds promote structural and functional neural plasticity.

Rather than simply altering neurotransmitter activity for a few hours, psychedelics appear capable of stimulating longer-lasting changes in neuronal connectivity.

These compounds are increasingly described as psychoplastogens, reflecting their ability to encourage structural remodelling within neural circuits.

The review discusses several complementary approaches for measuring these changes.

Structural plasticity

Researchers increasingly use advanced imaging methods to observe changes in dendritic spines and synaptic architecture following psychedelic administration.

Although technically demanding, in vivo two-photon microscopy allows repeated imaging of neuronal structures in living animals, providing direct evidence of structural remodelling over time.

The review notes that these in vivo measurements demonstrated substantially greater statistical power than comparable ex vivo analyses, highlighting their value despite lower throughput.

Functional plasticity

Beyond structural changes, psychedelics may also modify synaptic strength and metaplasticity.

Electrophysiological techniques allow researchers to examine how neuronal circuits respond after treatment, although these approaches currently remain relatively low throughput.

Gene expression

The authors also highlight growing interest in transcriptomics and immediate early gene mapping.

Techniques such as whole-brain c-Fos mapping, light-sheet microscopy, calcium imaging, and single-cell RNA sequencing provide increasingly detailed insights into the cellular pathways activated by psychedelic compounds.

Although current transcriptomic studies remain relatively small because of cost, advances in sequencing technologies are expected to make these methods increasingly practical for drug discovery.

Building Better Translational CNS Biomarkers

One of the strongest themes throughout the review is the need to improve translation from laboratory studies to human clinical trials.

Historically, many CNS drug candidates have shown encouraging preclinical results only to fail during clinical development.

Image

The authors highlight several technologies that could help bridge this gap.

Emerging translational approaches

Together, these technologies provide objective biomarkers that may improve confidence before compounds progress into costly Phase I and Phase II clinical trials.

They also support a broader industry trend towards mechanism-based drug discovery, where biological evidence is integrated across molecular, cellular, circuit, and behavioural levels rather than relying on a single experimental endpoint.

Why Non-Hallucinogenic Psychedelics Are Attracting Attention

One of the most active areas of psychedelic research involves compounds designed to retain therapeutic potential while reducing or eliminating hallucinogenic effects.

The review identifies this as one of the field's most important unanswered questions.

Researchers are investigating whether non-hallucinogenic 5-HT2A receptor agonists can stimulate beneficial neural plasticity without inducing the profound perceptual changes associated with classic psychedelics.

If successful, these compounds could expand treatment options for patients who may not be suitable candidates for psychedelic-assisted psychotherapy and could simplify clinical implementation by reducing the need for intensive supervised treatment sessions.

At the same time, the authors caution that key scientific questions remain unresolved.

It is still unclear whether structural neural plasticity alone is sufficient to produce durable clinical benefits, which signalling pathways are most closely linked to therapeutic outcomes, and whether different psychedelic classes share common mechanisms of action.

These unanswered questions illustrate why psychedelic drug discovery increasingly depends on integrating pharmacology, behavioural science, neurobiology, and translational biomarkers rather than relying on any single preclinical assay.

View interview AI in Pharma: Hype vs. What Actually Works

AI in Pharma: Hype vs. What Actually Works

Expert Lara Masad explains why pharma leaders miscalculate AI investments and how to build a defensible validation strategy.

Image

From Better Assays to Better CNS Medicines

The review concludes that the next wave of psychedelic medicines will not be defined simply by discovering new molecules. Instead, success will depend on building a more predictive and translational drug discovery pipeline.

Rather than relying on isolated assays, researchers propose combining complementary evidence from receptor pharmacology, behavioural neuroscience, neural plasticity, molecular biology, and advanced imaging.

This integrated approach aims to identify compounds that demonstrate consistent biological activity across multiple levels of investigation before entering human trials.

For pharmaceutical companies, this strategy offers several potential advantages:

• Improved candidate selection by identifying compounds with stronger translational evidence.
• Earlier identification of failure risks, reducing costly late-stage attrition.
• Greater confidence in mechanism of action, supporting regulatory discussions.
• More efficient optimisation of lead compounds through better understanding of structure-activity relationships.
• A stronger foundation for biomarker-driven clinical development, helping link preclinical findings with patient outcomes.

Image

The review argues that no single assay can currently predict clinical success. Instead, combining multiple orthogonal datasets creates a more complete picture of therapeutic potential and reduces reliance on any one experimental model.

The Future of Next-Generation CNS Drug Discovery

The implications extend well beyond psychedelic medicines.

Many neurological and psychiatric disorders continue to have limited treatment options despite decades of research investment.

Depression, schizophrenia, bipolar disorder, post-traumatic stress disorder (PTSD), and substance use disorders remain areas of high unmet medical need, while CNS drug development continues to experience some of the highest failure rates in pharmaceutical R&D.

The multidisciplinary framework proposed in the review could therefore influence drug discovery across the wider neuroscience landscape.

Several technologies highlighted by the authors are already reshaping preclinical research:

High-throughput pharmacology

Modern receptor screening platforms enable researchers to evaluate thousands of compounds rapidly, identifying candidates with specific signalling profiles rather than simply measuring receptor binding.

Advanced neuroscience tools

Techniques such as two-photon microscopy, calcium imaging, whole-brain mapping, and single-cell sequencing provide unprecedented insight into how candidate medicines alter neural circuits.

Artificial intelligence and computational modelling

Machine learning is increasingly supporting medicinal chemistry by predicting receptor interactions, prioritising compounds for synthesis, and analysing complex biological datasets that would be difficult to interpret manually.

Together, these advances are helping create a more data-rich and mechanism-driven approach to CNS drug discovery.

Remaining Scientific Challenges for Psychedelic Therapeutics

Despite the optimism surrounding psychedelic therapeutics, the review also highlights several important limitations.

First, translation remains the field's greatest challenge. Many promising findings in animal models have yet to demonstrate equivalent benefits in humans.

Improving the predictive value of preclinical assays remains essential if psychedelic drug discovery is to deliver clinically meaningful medicines.

Second, researchers are still working to determine which biological mechanisms are most closely linked to long-term therapeutic outcomes.

While activation of the 5-HT2A receptor is clearly important, questions remain about the relative contributions of receptor signalling, neuroplasticity, network remodelling, and psychological experience.

Finally, there is growing interest in developing non-hallucinogenic psychoplastogens, but these programmes remain at an early stage. Whether therapeutic benefits can be fully separated from altered states of consciousness is still an active area of investigation and will require robust clinical evidence.

These uncertainties reinforce the review's central message: Psychedelic drug discovery must be guided by rigorous science rather than enthusiasm alone.

Why It Matters for Pharmaceutical R&D

The resurgence of psychedelic research reflects a broader shift in pharmaceutical innovation.

Drug discovery is increasingly moving away from reductionist approaches that rely on single targets or isolated assays and towards integrated platforms that combine molecular biology, neuroscience, computational modelling, and translational biomarkers.

The review provides a practical roadmap rather than a catalogue of laboratory techniques. It demonstrates how combining multiple complementary datasets can strengthen confidence in candidate selection before compounds reach expensive clinical development.

If adopted more widely, this framework could help pharmaceutical companies:

• Reduce preclinical uncertainty.
• Improve decision-making at the lead optimisation stage.
• Prioritise compounds with stronger mechanistic evidence.
• Increase the likelihood that laboratory findings translate into meaningful clinical outcomes.

While psychedelic medicines continue to attract considerable scientific and commercial interest, the review suggests that the greatest innovation may lie in how these drugs are discovered rather than in the compounds themselves.

As the Global Intelligence Platform for Life Sciences industry, Pharmatica delivers expert analysis of the technologies, scientific breakthroughs, and regulatory developments shaping the future of pharmaceutical innovation. From Therapeutic Drug Discovery and Clinical Development to Advanced Manufacturing and HealthTech, Pharmatica provides decision-makers with trusted Insights that bridge cutting-edge research and real-world industry strategy.

Pharmatica: Insight. Connection. Impact.

Image